Board Changes Press Release
Ms. Enright brings more than 30 years of experience as a healthcare company executive and investor. She currently serves as Managing Partner at Prettybrook Partners, overseeing approximately 20 active investments in a variety of healthcare companies. Prior to her role at Prettybrook, Ms. Enright served as Chief Financial Officer of InfuSystem and as President of Lee Medical.
Mr. Zulueta has more than three decades of experience in global strategic and leadership roles within large pharma, specifically with Eli Lilly and Company. At Eli Lilly, he held key senior positions including Vice President of Global Marketing, head of the Company’s Asia Region, and most recently as President of International responsible for all geographies outside the United States and Canada.
Following the 2022 Annual Meeting - with the addition of Ms. Enright and Mr. Zulueta, and the planned retirements of Mr. Stack and Mr. Zakrzewski - the Amarin Board will comprise eight directors, seven of whom are independent.
About Erin Enright
Ms. Enright has served as a Managing Partner of Prettybrook Partners since 2012. Prior to that, she served as Chief Financial Officer of InfuSystem from 2005 to 2007, and as President of Lee Medical, a medical device manufacturer, from 2004 to 2013. From 1993 to 2003, Ms. Enright was with Citigroup, where she was Managing Director in its Equity Capital Markets group. While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. She began her career as an attorney with Wachtell, Lipton, Rosen & Katz.
Ms. Enright currently serves as Chairman of the Board of Dynatronics Corporation, a director of the Medical Facilities Corporation Board serving as Audit and Investment Committee Chair, a member of the Board and Chair of the Audit Committee of Brooklyn ImmunoTherapeutics (NASDAQ:BTX), and a director of Keystone Dental, a privately held company where she serves as Audit Committee Chair. She has previously served as a director at Biolase, Inc., Tigerlabs and Ceelite Corporation.
Ms. Enright received her A.B. degree from the School of Public and International Affairs at Princeton University and J.D. degree from the University of Chicago Law School.
About Alfonso “Chito” Zulueta
Prior to Mr. Zulueta’s retirement in 2021, he spent over three decades at Eli Lilly and Company in various roles of increasing responsibility, including most recently as President, International from 2017 until his retirement. He was a corporate officer and member of Eli Lilly and Company’s executive committee.
Mr. Zulueta currently serves on the Board of CTS Corporation where he serves on the audit and nominating and governance committees and Syneos Health as well as Glooko and Calidi Biotherapeutics, both privately held companies. He previously served as a member of the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and US-Japan Business Council.
He received his Bachelor of Arts from De La Salle University in the Philippines, and his MBA from Colgate Darden Graduate School of Business Administration at the University of Virginia.
